Fiduciary Trust Co. held its position in GlaxoSmithKline PLC (NYSE:GSK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,129 shares of the pharmaceutical company’s stock at the end of the 2nd quarter. Fiduciary Trust Co.’s holdings in GlaxoSmithKline PLC were worth $954,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in GSK. Russell Investments Group Ltd. acquired a new stake in GlaxoSmithKline PLC in the 1st quarter valued at approximately $578,000. Advisory Services Network LLC acquired a new stake in GlaxoSmithKline PLC in the 1st quarter valued at approximately $137,000. GFS Advisors LLC grew its holdings in GlaxoSmithKline PLC by 105.2% in the 1st quarter. GFS Advisors LLC now owns 10,869 shares of the pharmaceutical company’s stock valued at $458,000 after buying an additional 5,573 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in GlaxoSmithKline PLC by 15.2% in the 1st quarter. Sequoia Financial Advisors LLC now owns 6,500 shares of the pharmaceutical company’s stock valued at $274,000 after buying an additional 859 shares during the last quarter. Finally, Vantage Investment Partners LLC grew its holdings in GlaxoSmithKline PLC by 589.6% in the 1st quarter. Vantage Investment Partners LLC now owns 269,408 shares of the pharmaceutical company’s stock valued at $11,358,000 after buying an additional 230,339 shares during the last quarter. 9.28% of the stock is currently owned by hedge funds and other institutional investors.
GSK has been the topic of a number of research analyst reports. Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. ValuEngine lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub lowered GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $44.67.
GlaxoSmithKline PLC (NYSE:GSK) opened at 40.58 on Friday. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.54. The company has a market cap of $99.18 billion, a P/E ratio of 40.10 and a beta of 1.03. The company’s 50 day moving average price is $39.76 and its 200 day moving average price is $41.75.
GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities research analysts anticipate that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be given a dividend of $0.491 per share. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.84%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is currently 197.00%.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with our FREE daily email newsletter.